RTTNews | Dec 20, 2021 10:44AM EST

10:43 Monday, December 20, 2021 (RTTNews.com) - Shares of argenx SE (ARGX) are up more than 8% Monday morning.

On Friday, the FDA had approved argenx's VYVGART for the treatment of adults patients with generalized myasthenia gravis.

Generalized myasthenia gravis is a rare and chronic neuromuscular disease characterized by debilitating and potentially life-threatening muscle weakness.

ARGX is at $337.02 currently. It has traded in the range of $248.21- $382.15 in the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3250583/argenx-trading-8-up-in-morning-trade.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved